190A.T
Chordia Therapeutics Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 72.00
+2.86%Price chart
Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
JPY 5.02B
MomentumView details →
1D Return
+2.86%
YTD Return
−34.26%
RSI (14)
38.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
JPY 5.02B
RSI (14)
38.2
MomentumView details →
1D Return
+2.86%
YTD Return
−34.26%
Similar companies
Latest newsMore news →
Chordia Therapeutics announced on August 25, 2026 that Japan's Ministry of Health, Labour and Welfare granted rare disease drug designation to its CLK inhibitor rogocekib for relapsed or refractory acute myeloid leukemia (AML).10d agoChordia Therapeutics announced that its collaborative research results on MALT1 with University of Miyazaki, Kyoto University, and National Cancer Center Japan were published in the journal iScience on July 23, 2026.29d agoChordia Therapeutics' rogocekib (CTX-712) advanced to an expansion cohort in its Phase 1/2 clinical trial for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.50d ago